Epigenetic changes in tumor Fas levels determine immune escape and response to therapy

Cancer Cell

Volumn 2, Issue 2, 2002, Pages 139-148

  Maecker, Heather L ^a,c   Yun, Zhong ^a   Maecker, Holden T ^b   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b BD BIOSCIENCES   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TRICHOSTATIN A; HLA ANTIGEN CLASS 1; HYDROXAMIC ACID;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CULTURE; CELL DIVISION; CELL TRANSFORMATION; DISEASE COURSE; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE MUTANT; NATURAL KILLER CELL; NEOPLASM; NOTE; PATHOLOGY; TIME;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HYDROXAMIC ACIDS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037752001     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00095-8     Document Type: Article

References (45)

1. Adachi, M., Watanabe-Fukunaga, R., and Nagata, S. (1993). Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA 90, 1756-1760.
2. Adachi, M., Suematsu, S., Kondo, T., Ogasawara, J., Tanaka, T., Yoshida, N., and Nagata, S. (1995). Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 11, 294-300.
3. Adachi, M., Suematsu, S., Suda, T., Watanabe, D., Fukuyama, H., Ogasawara, J., Tanaka, T., Yoshida, N., and Nagata, S. (1996). Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad. Sci. USA 93, 2131-2136.
4. Alderson, M.R., Armitage, R.J., Maraskovsky, E., Tough, T.W., Roux, E., Schooley, K., Ramsdell, F., and Lynch, D.H. (1993). Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178, 2231-2235.
5. Ashkenazi, A., and Dixit, V.M. (1998). Death receptors: signaling and modulation. Science 281, 1305-1308.
6. Baker, B.W., Boettiger, D., Spooncer, E., and Norton, J.D. (1992). Efficient retroviral-mediated gene transfer into human B lymphoblastoid cells expressing mouse ecotropic viral receptor. Nucleic Acids Res. 20, 5234.
7. Bennett, M., Macdonald, K., Chan, S.W., Luzio, J.P., Simari, R., and Weissberg, P. (1998). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290-293.
8. Booker, J.K., Reap, E.A., and Cohen, P.L. (1998). Expression and function of Fas on cells damaged by gamma-irradiation in B6 and B6/lpr mice. J. Immunol. 161, 4536-4541.
9. Bradley, M., Zeytun, A., Rafi-Janajreh, A., Nagarkatti, P.S., and Nagarkatti, M. (1998). Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood 92, 4248-4255.
10. Coffey, D.C., Kutko, M.C., Glick, R.D., Swendeman, S.L., Butler, L., Rifkind, R., Marks, P.A., Richon, V.M., and LaQuaglia, M.P. (2000). Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol. 35, 577-581.
11. Eichhorst, ST., Muerkoster, S., Weigand, M.A., and Krammer, P.H. (2001). The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res. 61, 243-248.
12. Evan, G.I., and Vousden, K.H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
13. Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middleton, L.A., Lin, A.Y., Strober, W., Lenardo, M.J., and Puck, J.M. (1995). Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946.
14. Friesen, C., Herr, I., Krammer, P.H., and Debatin, K.M. (1996). Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2, 574-577.
15. Fruhwald, M.C., O'Dorisio, M.S., Dai, Z., Tanner, S.M., Balster, D.A., Gao, X., Wright, F.A., and Plass, C. (2001). Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene 20, 5033-5042.
16. Houghton, J.A., Harwood, F.G., and Tillman, D.M. (1997). Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc. Natl. Acad. Sci. USA 94, 8144-8149.
17. Ishido, S., Choi, J.K., Lee, B.S., Wang, C., DeMaria, M., Johnson, R.P., Cohen, G.B., and Jung, J.U. (2000). Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13, 365-374.
18. Johnsen, A.K., Templeton, D.J., Sy, M., and Harding, C.V. (1999). Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J. Immunol. 163, 4224-4231.
19. Johnstone, R.W., Ruefli, A.A., and Lowe, S.W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
20. Kolbus, A., Herr, I., Schreiber, M., Debatin, K.M., Wagner, E.F., and Angel, P. (2000). c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol. Cell. Biol. 20, 575-582.
21. Long, E.O., Burshtyn, D.N., Clark, W.P., Peruzzi, M., Rajagopalan, S., Rojo, S., Wagtmann, N., and Winter, C.C. (1997). Killer cell inhibitory receptors: diversity, specificity, and function. Immunol. Rev. 155, 135-144.
22. Maecker, H.L., Koumenis, C., and Giaccia, A.J. (2000). p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res. 60, 4638-4644.
23. Malik, K., Salpekar, A., Hancock, A., Moorwood, K., Jackson, S., Charles, A., and Brown, K.W. (2000). Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor. Cancer Res. 60, 2356-2360.
24. Manos, E.J., and Jones, D.A. (2001). Assessment of tumor necrosis factor receptor and Fas signaling pathways by transcriptional profiling. Cancer Res. 61, 433-438.
25. Marks, P.A., Richon, V.M., and Rifkind, R.A. (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216.
26. Matzke, M., Matzke, A.J., and Kooter, J.M. (2001). RNA: guiding gene silencing. Science 293, 1080-1083.
27. Maudsley, D.J., and Pound, J.D. (1991). Modulation of MHC antigen expression by viruses and oncogenes. Immunol. Today 12, 429-431.
28. Montel, A.H., Bochan, M.R., Hobbs, J.A., Lynch, D.H., and Brahmi, Z. (1995). Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 166, 236-246.
29. Morgenstern, J.P., and Land, H. (1990a). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
30. Morgenstern, J.P., and Land, H. (1990b). A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res. 18, 1068.
31. Munsch, D., Watanabe-Fukunaga, R., Bourdon, J.C., Nagata, S., May, E., Yonish-Rouach, E., and Reisdorf, P. (2000). Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J. Biol. Chem. 275, 3867-3872.
32. Nagata, S. (1994). Mutations in the Fas antigen gene in lpr mice. Semin. Immunol. 6, 3-8.
33. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
34. Newton, K., and Strasser, A. (2000). Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J. Exp. Med. 191, 195-200.
35. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396.
36. Peli, J., Schroter, M., Rudaz, C., Hahne, M., Meyer, C., Reichmann, E., and Tschopp, J. (1999). Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18, 1824-1831.
37. Ravetch, J.V., and Lanier, L.L. (2000). Immune inhibitory receptors. Science 290, 84-89.
38. Screpanti, V., Wallin, R.P., Ljunggren, H.G., and Grandien, A. (2001). A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167, 2068-2073.
39. Siegel, R.M., Chan, F.K., Chun, H.J., and Lenardo, M.J. (2000). The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1, 469-474.
40. Soloski, M.J. (2001). Recognition of tumor cells by the innate immune system. Curr. Opin. Immunol. 13, 154-162.
41. Struhl, K. (1998). Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606.
42. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995). Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
43. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317.
44. Wong, I.H., Lo, Y.M., Yeo, W., Lau, W.Y., and Johnson, P.J. (2000). Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6, 3516-3521.
45. Zheng, L.M., Ojcius, D.M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H., Chen, J., Wang, X.Y., Catino, J.J., and King, I. (1996). Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184, 579-584.